Xenon Pharmaceuticals Inc.

XENE Healthcare Biotechnology

Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

33.55 0.78 −2.27%
Market cap
$3.3B
P/E
0.0×
Fwd P/E
−10.7×
Dividend yield
—
F-score
n/a
Altman Z
37.76
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
— — — 3 3 — — — 1 2
P/E ratio
0.00 — — 0.00 0.00 0.00 0.00 — 0.00 0.00
P/S ratio
209.76 — — 171.27 73.92 16.52 47.84 — 166.55 67.45
Altman Z-Score
37.76 — — 43.34 37.06 16.50 1.21 — (3.53) 16.92
Altman Z″-Score (non-manufacturers)
6.89 — — 24.99 29.56 9.97 (1.22) — (7.50) 15.38
P/FCF ratio
0.00 — — 0.00 0.00 0.00 0.00 — 0.00 0.00
Beneish M-Score
— — — 1.12 (1.63) 1.94 — — 5.34 (0.58)
P/Operating CF
(43.59) — — (68.92) (65.81) (40.51) 17.19 — (7.57) (26.04)
P/B ratio
6.11 — — 3.13 2.51 3.25 4.04 — 1.44 1.90
EV/Sales
178.92 — — 128.33 45.44 11.84 30.14 — 48.02 31.88
EV/EBITDA
0.00 — — 0.00 0.00 0.00 0.00 — 0.00 0.00
EV/FCF
(10.82) — — (16.68) (11.71) (7.50) (35.98) — (0.51) (2.90)
Current Ratio
13.42 17.85 23.65 26.44 39.03 12.30 3.34 29.46 10.98 18.31
Net Debt/EBITDA
1.48 2.27 3.01 4.64 7.07 5.81 3.01 2.81 1.16 2.68
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.17 0.15 0.19 0.00
ROE
(51.76%) (27.85%) (22.12%) (19.77%) (21.84%) (22.60%) (44.52%) (48.09%) (61.51%) (36.81%)
ROA
(48.34%) (26.58%) (21.22%) (18.84%) (20.25%) (16.63%) (29.64%) (37.52%) (54.05%) (34.99%)
ROIC
(709.28%) (136.38%) (46.16%) (62.37%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(65.57%) (38.42%) (29.07%) (21.39%) (14.04%) (16.42%) (38.81%) (26.75%) (73.44%) (36.22%)
Average Days of Receivables
66.72 0.00 0.00 38.15 54.74 20.67 43.45 0.00 514.05 40.49
Earnings Yield
(9.73%) — — (5.48%) (5.95%) (5.30%) (11.75%) — (59.38%) (18.85%)
Free Cash Flow Yield
(7.88%) — — (4.49%) (5.25%) (9.55%) (1.75%) — (56.07%) (16.32%)
Free Cash Flow per Share
(3.53) (2.37) (2.34) (1.67) (1.64) (1.47) (0.23) (1.81) (1.61) (1.28)
Book value per Share
7.34 9.69 13.87 11.92 12.61 4.96 3.55 5.32 2.00 4.12
Free Cash Flow
(279.92) (184.46) (156.73) (101.32) (71.55) (50.76) (5.95) (35.23) (29.04) (19.85)
EV/EBIT
0.00 — — 0.00 0.00 0.00 0.00 — 0.00 0.00
Other line items

Show all line items

Columns are period end dates